Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of June 2020, with a specific transaction date of June 9, 2020. The document serves as a transaction notification regarding the acquisition of ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively details specific share transactions.
| Instrument | Transaction Type | Price per Share | Total Volume | Exchange |
|---|---|---|---|---|
| Ordinary Shares (25p each) | Acquisition (Share Reward Plan) | £16.6211 | 148 shares (aggregate) | London Stock Exchange (XLON) |
Note: The aggregate volume of 148 shares is derived from 11 individual transactions, mostly involving 16 shares each (8 partnership + 8 matching), with one transaction involving 14 shares.
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It strictly reports routine compliance disclosures for insider share acquisitions.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of specific equity transactions.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of ordinary shares under the Company's Share Reward Plan, not open market sales or purchases.
- Participants: Transactions involved senior executives including the CEO (Ms E Walmsley), President of Global Vaccines (Mr R Connor), and other SVPs and officers.
- Share Price: The uniform transaction price was £16.6211 per share.
- Volume: Individual transaction volumes were minimal (14 or 16 shares per person), indicating standard plan participation rather than significant capital movement.
- Financial Data: Investors should refer to GSK's Form 20-F or quarterly earnings releases for actual revenue, profit, and cash flow data, as this document does not provide them.